Artizan Biosciences

Artizan Biosciences is a biopharmaceutical company focused on developing drugs targeting the gut microbiome to treat diseases such as chronic inflammation. Artizan Biosciences is leveraging the human gut as a drug discovery tool to create novel precision therapies for chronic inflammation and immune dysregulation. The company’s innovative platform employs multiple approaches to disrupt gut-related triggers of the inflammatory process, with a particular focus on small molecule inhibitors. In doing so, Artizan has created a new class of molecules called GEMMi, which are Gut-Exclusive Microbial Metalloproteinase Inhibitors. These compounds are designed to precisely target pathogenic mechanisms that act as inflammatory triggers in patients with inflammatory bowel disease (“IBD”).